



Tollys moves its headquarters

Lyon, France, December 8, 2021 - Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic agonist specific to the Toll-like receptor 3 (TLR3), announced today that it has moved its headquarters to the BIOSERRA 2 research park of Lyon, at 60F avenue Rockefeller, 69008 Lyon, France.

Vincent Charlon, CEO of Tollys SAS said: "This move to our new headquarters allows our team to work not only in our own research laboratories but also near the scientific and medical communities. This new space is specifically designed for biotech companies and will support our developments very efficiently."

The new 300 sqm headquarters will support Tollys' growth by offering all the features expected by biotech companies. The company has signed a long-term lease agreement and has set up a 170 sqm laboratory adapted to its current needs but also to its future developments.

About TL-532

Tollys has discovered and patented a family of TLR3 agonists and has selected TL-532 as its lead candidate. TL-532 is a structurally defined, synthetically produced, double-stranded RNA that is highly specific for the TLR3 receptor. The specificity for the TLR3 receptor and its defined 70-base-pair sequence differentiates TL-532 from all other TLR3 agonists tested to date in clinical trials.

About Tollys

Founded in 2015, the company has raised a total of €7M from private investors to date and has secured €1.5M in funding from Bpifrance under the Deeptech program. In May 2021, Tollys was awarded the distinction of "Best-in-class therapeutic innovation" by the international board of the MATWIN program. Tollys was awarded this prize for the medical interest and industrial development potential of TL-532, its specific TLR3 receptor agonist. The MATWIN program, which is based on a long-standing partnership with some fifteen international laboratories including Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Gilead, GSK, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi, has enabled Tollys to present its state-of-the-art research programs to the world's leading experts in anti-cancer treatments.

www.tollys.fr
contact@tollys.fr